

# ForPatients

by Roche

Hepatitis B Virus

## A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

**Trial Status**  
Terminated

**Trial Runs In**  
9 Countries

**Trial Identifier**  
NCT03762681 NP40520

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses in healthy volunteers (HV) and participants diagnosed with chronic hepatitis B (CHB).

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT03762681 NP40520**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=18 Years & <= 65 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

---